| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/27/2006 | WO2006077675A1 Fibrosis inhibitor for implanted organ |
| 07/27/2006 | WO2006053555A3 Pyrazol-3-one and/or pyridazin-3-one derivatives used as inhibitors of lysyl oxidase |
| 07/27/2006 | WO2006047372A3 Lamotrigine analogs |
| 07/27/2006 | WO2006044582A3 Use of baff to treat sepsis |
| 07/27/2006 | US20060168672 B7-like molecules and uses thereof |
| 07/27/2006 | US20060167637 System and methods for optimized drug delivery and progression of diseased and normal cells |
| 07/27/2006 | US20060167402 Method and composition for inhibiting cardiovascular cell proliferation |
| 07/27/2006 | US20060167276 Clausenamide c5-hydroxyl derivatives and n-substituted derivatives, processes for their preparation, its composition and use |
| 07/27/2006 | US20060167261 e.g. N-(4-Chloro-3-trifluoro methyl phenyl)-2-[3-(4-pyridinyloxy)phenyl amino]-acetamide; serine/threonine kinase inhibitor; anticarcinogenic, antiproliferative, antidiabetic agent; autoimmune diseases; atherosclerosis, arthritis, Crohn's disease, retinopaty |
| 07/27/2006 | US20060167251 CCR9 inhibitors and methods of use thereof |
| 07/27/2006 | US20060167237 Derivatives of monosaccharides for drug discovery |
| 07/27/2006 | US20060167105 CCR-3 receptor antagonists |
| 07/27/2006 | US20060167098 Method for the treatment of diseases linked to an accumulation of triglycerides and cholesterol |
| 07/27/2006 | US20060167086 Medicinal composition |
| 07/27/2006 | US20060167083 Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures |
| 07/27/2006 | US20060167080 Use in inhibiting PI-3-kinase activity in mammals; cancer; Acetic acid 4-diallylaminomethylene-6-hydroxy-1- alpha -methoxymeth-yl-10 beta ,13 beta -dimethyl-3,7,17-trioxo-1,3,4,7,10,11 beta , 12,13,14 alpha ,15,16,17-dodecahydro-2-oxa-cyclopenta[ alpha ]phenanthren-11-yl ester |
| 07/27/2006 | US20060167067 Gm-95-containing antitumor effect potentiator, combined antitumor preparation and antitumor agent |
| 07/27/2006 | US20060167059 Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| 07/27/2006 | US20060167053 e.g. 3-(6-ethanesulfonylpyridin-3-yloxy)-5-(2-hydroxy-1-methyl-ethoxy)-N-(1-methyl-1H-pyrazol-3-yl)benzamide; glucokinase activator; antidiabetic agent; obesity, insulin resistance |
| 07/27/2006 | US20060167052 Piperidine derivative, process for producing the same, and use |
| 07/27/2006 | US20060167048 N-4-piperidinyl compounds as ccr5 modulators |
| 07/27/2006 | US20060167043 Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
| 07/27/2006 | US20060167038 2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide; preventive, therapeutic agent and analgesic for overactive bladder |
| 07/27/2006 | US20060167036 Receptor or non-receptor; 5,6,7,8,9,10-hexahydro-6,9-(epiminomethano) benzo[ alpha ][8]annulenes; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor |
| 07/27/2006 | US20060167034 Novel benzonaphthyridines |
| 07/27/2006 | US20060167032 Pharmaceutical composition and method for treating disorders of the central nervous system |
| 07/27/2006 | US20060167026 Antipsychotic molecular-targeting epithelial growth factor receptor |
| 07/27/2006 | US20060167015 Inhibitors of tyrosine kinases |
| 07/27/2006 | US20060167013 5-methyl-2-(1-piperazinyl)benzenesulfonic acid; sodium channel blocking agent; cardiovascular disorder : ischemic heart disease, reperfusion, heart failure, hypertension, angina pectoris, arrhythmia, postsurgery complications |
| 07/27/2006 | US20060167011 Inhibitors of phosphorylation of platelet derived growth factor receptor |
| 07/27/2006 | US20060167007 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof |
| 07/27/2006 | US20060167005 New therapeutic uses of (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl) thieno [2,3-d] pyrimidine |
| 07/27/2006 | US20060167002 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists |
| 07/27/2006 | US20060167001 Pyridazinone-derivatives as pde4 inhibitors |
| 07/27/2006 | US20060166999 Use of microsomal triglyceride transfer protein (MTP) inhibitors for reducing the number of postprandial triglyceride-rich lipoprotein particles (PPTRL) |
| 07/27/2006 | US20060166989 2-naphthamide derivatives |
| 07/27/2006 | US20060166978 Inhibitors of IkB kinase (I Kappa B Kinase); 1-acetyl-7-bromo- beta -carboline; antiinflammatory and anticarcinogenic agent; asthma, osteoarthritis, rheumatoid arthritis, Alzheimer's disease, infections, and cardiac infarct |
| 07/27/2006 | US20060166961 Cell adhesion inhibitors |
| 07/27/2006 | US20060166940 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases |
| 07/27/2006 | US20060166934 Composition comprising phytosphingosine derivatives for apoptosis induction |
| 07/27/2006 | US20060166903 Phosphocholine linked prodrug derivatives |
| 07/27/2006 | US20060166899 prevention or treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. 4-[(4-{3-[1-carbamoyl-1-(methyl)-ethylcarbamoyl]propyl}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole |
| 07/27/2006 | US20060166880 Control a mechanism of intracellular release of calcium, to control signal transmission in which intracellular calcium is involved; to control intracellular calcium release by carbonic anhydrase-related protein (CARP), to regulate or diagnose activity of IP3R |
| 07/27/2006 | US20060166873 Preventive/remedy for arteriosclerosis |
| 07/27/2006 | US20060166872 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia |
| 07/27/2006 | US20060166871 Medical compositions containing ghrelin |
| 07/27/2006 | US20060166868 Vegf peptides and their use |
| 07/27/2006 | US20060166866 Cell adhesion inhibitors |
| 07/27/2006 | US20060166865 A modified nucleoside comprising a purine ring for treating viral infections |
| 07/27/2006 | US20060166863 Inhibitor and stimulator of stem cell proliferation and uses thereof |
| 07/27/2006 | US20060166274 G protein coupled receptor (GPCR) agonists and antagonists and methods of activating and inhibiting GPCR using the same |
| 07/27/2006 | US20060165808 Microcapsules for the delayed, controlled release of perindopril |
| 07/27/2006 | US20060165757 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/27/2006 | US20060165733 Liquid formulations with high concentration of hunan growth hormone (hgh) comprising phenol |
| 07/27/2006 | US20060165696 Remedy for spinal injury containing interleukin-6 antagonist |
| 07/27/2006 | US20060165689 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 07/27/2006 | US20060165683 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 07/27/2006 | US20060165672 Fatigue reducing agent |
| 07/27/2006 | US20060165656 Medicinal preparation having chemotherapeutic encapsulated therein |
| 07/27/2006 | US20060165619 Cosmetic composition for skin whitening comprising senkyunolide A as active ingredient |
| 07/27/2006 | US20060165607 Carbon dioxide external preparation and material for formation of carbon dioxide external preparation |
| 07/27/2006 | US20060165591 Metal complex-containing pharmaceutical agents |
| 07/27/2006 | CA2595063A1 Emulsified composition for dilution and cancer vaccine composition |
| 07/27/2006 | CA2594629A1 Fibrosis inhibitor for implanted organ |
| 07/26/2006 | EP1683863A2 A method for enhancing neurone survival and agents useful for same |
| 07/26/2006 | EP1683858A2 Viral preparations, vectors, immunogens, and vaccines |
| 07/26/2006 | EP1683805A1 Novel inhibitor for advanced glycation endproduct formation and aldose reductase inhibitor |
| 07/26/2006 | EP1683803A1 Water soluble prodrugs of hindered alcohols or phenols |
| 07/26/2006 | EP1683797A1 Heterocyclic spiro compound |
| 07/26/2006 | EP1683788A1 The derivatives of pyridone and the use of them |
| 07/26/2006 | EP1683527A1 Method of inhibiting secretase activity |
| 07/26/2006 | EP1683522A1 Use of benzoxazins in the manufacture of a medicament to prevent or treat acute tolerance to morphinic compounds |
| 07/26/2006 | EP1683520A2 Water-soluble paclitaxel produgs |
| 07/26/2006 | EP1682571A1 A bidentate motif and methods of use |
| 07/26/2006 | EP1682570A1 A binding motif and methods of regulating cell function |
| 07/26/2006 | EP1682504A2 Hydroxy piperidine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682135A1 Ccr-2 antagonist salt |
| 07/26/2006 | EP1682134A2 Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease |
| 07/26/2006 | EP1682122A1 Combinations of at1-antagonists, amiloride or triamterine, and a diuretic |
| 07/26/2006 | EP1682121A1 Use of crth2 antagonist compounds in therapy |
| 07/26/2006 | EP1682119A1 Discodermolide compositions |
| 07/26/2006 | EP1682072A2 AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT |
| 07/26/2006 | EP1527063B1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 07/26/2006 | EP1513839B1 3-substituted quinuclidines and their use |
| 07/26/2006 | EP1485140B1 Polymer composite loaded with cells |
| 07/26/2006 | EP1465921B1 Corticotropin releasing factor receptor 2 agonists |
| 07/26/2006 | EP1448552B1 Quinoline derivatives, process for preparing them and use for the treatment of diseases mediated by s-cd23 |
| 07/26/2006 | EP1414447B1 Use of thiazole derivatives for preparing a medicine for protecting mitochondria |
| 07/26/2006 | EP1397105B1 Compositions for inhibiting angiogenesis |
| 07/26/2006 | EP1392329B1 Use of sulodexide for the treatment of inflammatory bowel disease |
| 07/26/2006 | EP1373215B1 Geldanamycin derivatives useful for treating cancer |
| 07/26/2006 | EP1359905B1 Use of mglur5 antagonists for the treatment of pruritic conditions |
| 07/26/2006 | EP1357906B1 Blockade of sodium channels by phenol derivatives |
| 07/26/2006 | EP1353919B1 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 07/26/2006 | EP1353687B1 Methods for obtaining inhibitors of tirc7 ligand binding and uses thereof |
| 07/26/2006 | EP1311297B1 A method for reducing stress-induced overproduction of neuropeptide y in an individual |
| 07/26/2006 | EP1303294B1 Method for treating unstable angina pectoris |
| 07/26/2006 | EP1263784B1 Novel human ulip/crmp protein and use thereof in diagnosis and treatment of cancers and paraneoplastic neurological syndromes |
| 07/26/2006 | EP1244451B1 Substituted piperazine and piperidine calcium channel blockers |
| 07/26/2006 | EP1240313B1 Homologue enzymes of human heparanase and splice variants thereof |